Approaches to First-In-Man and Beyond: Early Evidence of Target Engagement with Biomarkers and Innovative Clinical Trial Designs.Krishna_SII_28.02.06.ppt (2 MB)
J. Lesko
Tools to Reduce Phase III Trial Failures.1500_Lesko.ppt (560 kB)
J. Lütz
Perspective of the German Medicines Agency (BfArM). BfArM after reorganisation of the structure.J._L_tz_SVII_06.03.06.pdf (151 kB)